Radar›Companies›Top Surgical And Medical Instruments And Apparatus Stocks in USA
United States surgical and medical instruments and apparatus industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Top Surgical And Medical Instruments And Apparatus Stocks in USA

Five U.S.-listed surgical and medical instruments and apparatus names, read through one evidence stack: market path, official filing history, profitability, readiness, Prism attention and industry context.

Snapshot: 13 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderDexcom · 55
Strongest available pathGlobus Medical · +5.3%
Widest latest marginResMed · 27.2%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1DXCM · Nasdaq

Dexcom

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1999WILMINGTON$34.52B market cap
View full Companies Radar profile
55Moderate
Snapshot price$91.48as of page date
Monthly-close return-30.9%five-year window
FY2025 revenue$4.66BDEXCOM INC
Net margin17.9%FY2025
P/E snapshot35.9xone ratio, not a verdict
Prism attention13.1%share across these five
Filing track recordRevenue, USD billions
+90.4%
$0$1.6B$3.1B$4.7BFY2021: $2.449BFY2022: $2.910BFY2023: $3.622BFY2024: $4.033BFY2025: $4.662B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 17.5%
52-week position100% through range
$54.11$91.62
News mentions7.3K
Community mentions83.7Kpartial coverage
U.S.-scope patents4656
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal82/100
Management stability90/100
Market position7/100
Capital-event signal64/100
Innovation pulse15/100
Management signal

No leadership-churn flag in the model; 11 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 3 M&A involvements, 0 asset-acquisition events and 3 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2GMED · NYSE

Globus Medical

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2003WILMINGTON$11.54B market cap
View full Companies Radar profile
50Moderate
Snapshot price$85.94as of page date
Monthly-close return+5.3%five-year window
FY2025 revenue$2.94BGLOBUS MEDICAL INC
Net margin18.3%FY2025
P/E snapshot21.9xone ratio, not a verdict
Prism attention3.8%share across these five
Filing track recordRevenue, USD billions
+206.7%
$0$1.0B$2.0B$2.9BFY2021: $0.958BFY2022: $1.023BFY2023: $1.568BFY2024: $2.519BFY2025: $2.939B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 32.3%
52-week position67% through range
$54.15$101.4
News mentions2.1K
Community mentions61partial coverage
U.S.-scope patents5179
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal77/100
Management stability90/100
Market position23/100
Capital-event signal20/100
Innovation pulse15/100
Management signal

No leadership-churn flag in the model; 5 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 21 M&A involvements, 5 asset-acquisition events and 2 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3WST · NYSE

West Pharmaceutical Services

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1923EXTON$24.36B market cap
View full Companies Radar profile
45Cautious
Snapshot price$346.2as of page date
Monthly-close return-23.4%five-year window
FY2025 revenue$3.07BWEST PHARMACEUTICAL SERVICES INC
Net margin16.1%FY2025
P/E snapshot45.1xone ratio, not a verdict
Prism attention3.9%share across these five
Filing track recordRevenue, USD billions
+8.6%
$0$1.0B$2.0B$3.1BFY2021: $2.832BFY2022: $2.887BFY2023: $2.950BFY2024: $2.893BFY2025: $3.074B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 2.1%
52-week position75% through range
$223.8$386.0
News mentions2.2K
Community mentions12partial coverage
U.S.-scope patents459
Prism Insights

What sits behind the readiness signal

Observed risk 4/100higher means more observed risk
Earnings signal82/100
Management stability90/100
Market position8/100
Capital-event signal15/100
Innovation pulse5/100
Management signal

No leadership-churn flag in the model; 5 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 1 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 0 in the latest 360 days, and 2 company announcements in that window.

Recent risk watch

Recent available records contain 1 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4RMD · NYSE

ResMed

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 2010San Diego, California$32.89B market cap
View full Companies Radar profile
44Cautious
Snapshot price$226.7as of page date
Monthly-close return-22.0%five-year window
FY2025 revenue$5.15BRESMED INC
Net margin27.2%FY2025
P/E snapshot21.6xone ratio, not a verdict
Prism attention6.8%share across these five
Filing track recordRevenue, USD billions
+61.0%
$0$1.7B$3.4B$5.1BFY2021: $3.197BFY2022: $3.578BFY2023: $4.223BFY2024: $4.685BFY2025: $5.146B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 12.6%
52-week position41% through range
$180.3$293.8
News mentions3.8K
Community mentions22.9Kpartial coverage
U.S.-scope patents702
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal77/100
Management stability90/100
Market position16/100
Capital-event signal5/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 25 M&A involvements, 0 asset-acquisition events and 5 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5BAX · NYSE

Baxter

A U.S.-listed issuer classified by the SEC in Surgical And Medical Instruments And Apparatus

Founded 1931Deerfield, Illinois$13.98B market cap
View full Companies Radar profile
35Cautious
Snapshot price$27.05as of page date
Monthly-close return-64.5%five-year window
FY2025 revenue$11.24BBAXTER INTERNATIONAL INC
Net margin-8.5%FY2025
P/E snapshot13.3xone ratio, not a verdict
Prism attention72.4%share across these five
Filing track recordRevenue, USD billions
-12.0%
$0$5.0B$10.1B$15.1BFY2021: $12.784BFY2022: $15.113BFY2023: $14.813BFY2024: $10.636BFY2025: $11.244B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -3.2%
52-week position79% through range
$15.73$30.00
News mentions40.3K
Community mentions1.7Kpartial coverage
U.S.-scope patents11259
Prism Insights

What sits behind the readiness signal

Observed risk 12/100higher means more observed risk
Earnings signal41/100
Management stability55/100
Market position35/100
Capital-event signal34/100
Innovation pulse26/100
Management signal

Leadership churn is flagged elevated; 4 key-person events were recorded in the latest 360-day window.

Market activity

Available history contains 55 M&A involvements, 41 asset-acquisition events and 14 contract events.

Innovation activity

Prism records 1 lifetime product-launch events, 1 in the latest 360 days, and 5 company announcements in that window.

Recent risk watch

Recent available records contain 6 lawsuit, 0 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Globus Medical
+5.3%
ResMed
-22.0%
West Pharmaceutical Services
-23.4%
Dexcom
-30.9%
Baxter
-64.5%

Latest revenue

USD billions, official filing scope shown on each company card.

Baxter
$11.24B
ResMed
$5.15B
Dexcom
$4.66B
West Pharmaceutical Services
$3.07B
Globus Medical
$2.94B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

ResMed
27.2%
Globus Medical
18.3%
Dexcom
17.9%
West Pharmaceutical Services
16.1%
Baxter
-8.5%

Prism news attention

Normalized share across these five names; attention is not quality.

Baxter
72.4%
Dexcom
13.1%
ResMed
6.8%
West Pharmaceutical Services
3.9%
Globus Medical
3.8%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized surgical and medical instruments and apparatus news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Baxter leads the conversation

It holds 72.4% of measured surgical and medical instruments and apparatus news attention and also carries the basket's largest revenue base at $11.24B.

Price path

Globus Medical leads the available price paths

Its monthly-close return is +5.3% for the five-year window. At the other end, Baxter is -64.5% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

ResMed has the widest latest margin

Its FY2025 net margin is 27.2%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Baxter shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at 13.3x while its five-year window price return is -64.5%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · DXCM

Dexcom

7,265available Prism news records

Prism top themes

Price action & investor response
393
Macro demand & rates
234
Earnings & financial performance
184
Legal, arbitration & regulatory
125
Capital allocation & transactions
64

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-23.6%1,381 latest 12m vs 1,808 prior 12m
2024-01: 111 mentions2024-02: 92 mentions2024-03: 104 mentions2024-04: 64 mentions2024-05: 77 mentions2024-06: 127 mentions2024-07: 169 mentions2024-08: 216 mentions2024-09: 189 mentions2024-10: 189 mentions2024-11: 145 mentions2024-12: 156 mentions2025-01: 159 mentions2025-02: 224 mentions2025-03: 90 mentions2025-04: 87 mentions2025-05: 99 mentions2025-06: 85 mentions2025-07: 88 mentions2025-08: 95 mentions2025-09: 174 mentions2025-10: 111 mentions2025-11: 126 mentions2025-12: 108 mentions2026-01: 115 mentions2026-02: 153 mentions2026-03: 105 mentions2026-04: 139 mentions2026-05: 140 mentions2026-06: 27 mentions2024-012026-06

Machine-classified coverage tone

79.6% positive+18.5 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

flash glucose monitoring 198interstitial glucose monitoring 166advanced diabetes devices 145self-monitoring blood glucose 140glucose trends analysis 131glucose meter accuracy 129remote glucose monitoring 120continuous glucose monitor 119

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-18–2026-06-13 · trend and themes shown through 2026-06
Areas of research · GMED

Globus Medical

2,090available Prism news records

Prism top themes

Earnings & financial performance
112
Price action & investor response
80
Leadership & governance
40
Legal, arbitration & regulatory
25
Macro demand & rates
23

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-19.3%321 latest 12m vs 398 prior 12m
2024-01: 25 mentions2024-02: 28 mentions2024-03: 15 mentions2024-04: 16 mentions2024-05: 24 mentions2024-06: 30 mentions2024-07: 24 mentions2024-08: 56 mentions2024-09: 15 mentions2024-10: 23 mentions2024-11: 26 mentions2024-12: 6 mentions2025-01: 21 mentions2025-02: 86 mentions2025-03: 47 mentions2025-04: 18 mentions2025-05: 64 mentions2025-06: 12 mentions2025-07: 21 mentions2025-08: 24 mentions2025-09: 20 mentions2025-10: 24 mentions2025-11: 33 mentions2025-12: 16 mentions2026-01: 26 mentions2026-02: 39 mentions2026-03: 28 mentions2026-04: 43 mentions2026-05: 36 mentions2026-06: 11 mentions2024-012026-06

Machine-classified coverage tone

90.6% positive+7.8 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

earnings report 34quarterly results 27annual earnings 25financial report 23profit statement 21quarterly financials 20stock performance 17investment deal 13

Keyword tag occurrences in available Prism news records.

Coverage: 2010-03-16–2026-06-11 · trend and themes shown through 2026-06
Areas of research · WST

West Pharmaceutical Services

2,194available Prism news records

Prism top themes

Price action & investor response
186
Earnings & financial performance
114
Legal, arbitration & regulatory
73
Macro demand & rates
67
Capital allocation & transactions
62

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+105.1%562 latest 12m vs 274 prior 12m
2024-01: 18 mentions2024-02: 32 mentions2024-03: 16 mentions2024-04: 24 mentions2024-05: 19 mentions2024-06: 8 mentions2024-07: 14 mentions2024-08: 16 mentions2024-09: 21 mentions2024-10: 21 mentions2024-11: 16 mentions2024-12: 13 mentions2025-01: 19 mentions2025-02: 53 mentions2025-03: 22 mentions2025-04: 26 mentions2025-05: 31 mentions2025-06: 22 mentions2025-07: 31 mentions2025-08: 22 mentions2025-09: 28 mentions2025-10: 54 mentions2025-11: 27 mentions2025-12: 30 mentions2026-01: 69 mentions2026-02: 99 mentions2026-03: 54 mentions2026-04: 67 mentions2026-05: 66 mentions2026-06: 15 mentions2024-012026-06

Machine-classified coverage tone

91.4% positive+5.9 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

smart packaging 65anti-counterfeiting packaging 52temperature-sensitive packaging 44stock price 34drug distribution 33stock performance 30investment deal 20serialization pharmaceuticals 20

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-07–2026-06-15 · trend and themes shown through 2026-06
Areas of research · RMD

ResMed

3,762available Prism news records

Prism top themes

Price action & investor response
223
Earnings & financial performance
141
Macro demand & rates
91
Capital allocation & transactions
51
Leadership & governance
41

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+8.5%511 latest 12m vs 471 prior 12m
2024-01: 54 mentions2024-02: 23 mentions2024-03: 31 mentions2024-04: 47 mentions2024-05: 26 mentions2024-06: 36 mentions2024-07: 36 mentions2024-08: 47 mentions2024-09: 39 mentions2024-10: 39 mentions2024-11: 50 mentions2024-12: 14 mentions2025-01: 38 mentions2025-02: 87 mentions2025-03: 42 mentions2025-04: 53 mentions2025-05: 14 mentions2025-06: 12 mentions2025-07: 20 mentions2025-08: 38 mentions2025-09: 29 mentions2025-10: 41 mentions2025-11: 14 mentions2025-12: 23 mentions2026-01: 54 mentions2026-02: 70 mentions2026-03: 34 mentions2026-04: 96 mentions2026-05: 68 mentions2026-06: 24 mentions2024-012026-06

Machine-classified coverage tone

82.4% positive-2.1 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 51stock price 29earnings report 26investment deal 22bariatric surgery sleep apnea 20stock surge 20quarterly results 20non-hypercapnic central apnea 20

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-31–2026-06-12 · trend and themes shown through 2026-06
Areas of research · BAX

Baxter

40,277available Prism news records

Prism top themes

Leadership & governance
215
Earnings & financial performance
135
Capital allocation & transactions
93
Price action & investor response
72
Legal, arbitration & regulatory
50

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-31.3%3,137 latest 12m vs 4,568 prior 12m
2024-01: 317 mentions2024-02: 340 mentions2024-03: 332 mentions2024-04: 295 mentions2024-05: 353 mentions2024-06: 270 mentions2024-07: 311 mentions2024-08: 344 mentions2024-09: 293 mentions2024-10: 480 mentions2024-11: 415 mentions2024-12: 253 mentions2025-01: 296 mentions2025-02: 1,078 mentions2025-03: 320 mentions2025-04: 357 mentions2025-05: 247 mentions2025-06: 174 mentions2025-07: 260 mentions2025-08: 493 mentions2025-09: 241 mentions2025-10: 244 mentions2025-11: 213 mentions2025-12: 167 mentions2026-01: 237 mentions2026-02: 337 mentions2026-03: 317 mentions2026-04: 383 mentions2026-05: 208 mentions2026-06: 37 mentions2024-012026-06

Machine-classified coverage tone

66.9% positive-3.5 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

prosecutorial misconduct challenges 48earnings report 40prosecutorial misconduct 40lawyer series 37ceo change 36college playoffs 36stock performance 35financial report 31

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-01–2026-06-12 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

DXCM

Dexcom

83,701 mentions
Products, pricing and logistics
72,915
Stock and valuation
596
Workplace and hiring
139
Other company context
5

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 83,701 records remained after filtering.

GMED

Globus Medical

61 mentions
Stock and valuation
27
Products, pricing and logistics
5
Workplace and hiring
4

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 61 records remained after filtering.

RMD

ResMed

22,949 mentions
Products, pricing and logistics
20,932
Stock and valuation
80
Workplace and hiring
20

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 22,949 records remained after filtering.

BAX

Baxter

1,681 mentions
Products, pricing and logistics
546
Stock and valuation
99
Workplace and hiring
86
Other company context
1

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 1,681 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

DXCM

Dexcom

through 2026-04-30
Earnings releases 61Lawsuits 41Leadership changes 18Company announcements 9Listing / IPO 4
  1. Earnings releases

    Dexcom (Nasdaq:DXCM) today posted first-quarter results that came in ahead of the Wall Street forecast. Shares of DXCM fell nearly 6% to $55.99 apiece in post-market trading today. The San Diego-based continuous glucose monitor (CGM) developer reported profits. of $199.5 million. That equals 51¢ per share on sales of $1.19 billion for the three months ended March 31, 2026.

  2. Leadership changes

    Mark Foletta resumed his duties as lead independent director after serving as interim chair in Sayer’s absence.

  3. Lawsuits

    A California judge has dismissed several claims against Dexcom (Nasdaq:DXCM) officials related to alleged misrepresentation of sales efforts.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

GMED

Globus Medical

through 2026-02-26
Earnings releases 42M&A 11Leadership changes 7Asset acquisitions 1
  1. Earnings releases

    Company Earnings Amt % of Sales Sales $826.4 Cost of Sales $261.1 31.6% R & D $36.1 4.4% Selling and Admin $318.5 38.5% Other $70.1 8.5% Net Earnings $140.6 17%

  2. Leadership changes

    Daniel Scavilla has resigned as President and Chief Executive Officer to pursue another opportunity as President and CEO of Dentsply Sirona.

  3. M&A

    Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced the completion of its previously disclosed acquisition of Nevro Corp.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

WST

West Pharmaceutical Services

through 2026-04-23
Earnings releases 42Leadership changes 8Lawsuits 3Company announcements 2Asset acquisitions 1
  1. Earnings releases

    West Pharmaceutical Services updated its Q2 2026 guidance to 2.050-2.120 EPS.

  2. Company announcements

    West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, announced today the opening of its new building at its current site in Damastown, Dublin. The 165,000 square foot expansion significantly enhances West’s contract services.

  3. Leadership changes

    West Pharmaceutical Services, Inc. (NYSE: WST) announced today that Eric M. Green has informed the Board of Directors that he plans to retire from his positions as President, Chief Executive Officer and Chair of the Board of the Company once his successor has been hired in order to ensure a smooth transition.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

RMD

ResMed

through 2026-02-03
Earnings releases 53Leadership changes 14Company announcements 7M&A 5Business contracts 1
  1. Earnings releases

    Based on Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of A$1.45 billion and a net profit of A$399.08 million.

  2. Leadership changes

    Karen Drexler has served as a ResMed director since November 2017

  3. M&A

    Resmed (NYSE: RMD) + announced today that it acquired VirtuOx, a leading independent diagnostic testing facility (IDTF).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

BAX

Baxter

through 2026-05-01
Leadership changes 43Company announcements 34Earnings releases 33Lawsuits 31Asset acquisitions 14
  1. Earnings releases

    First quarter 2026, global sales from continuing operations totaled $2.7 billion and increased 3% on a reported basis and declined 1% on an organic basis. Adjusted earnings from continuing operations were $0.36 per share, a decrease of 35%.

  2. Board updates

    Shafer then became non-executive chair of the board as the board went forward with a previous plan to separate the roles of board chair and CEO.

  3. Lawsuits

    According to that complaint filed in the U.S. District Court for the Northern District of Illinois the plaintiff alleges that the defendants violated Federal Securities Laws.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Surgical And Medical Instruments And Apparatus Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary surgical and medical instruments and apparatus news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

surgical instruments market

9 sources77.7% extraction confidence
2019 extracted base$10.20B–$11.75B
2025 extracted forecast$11.50B–$21.52B
Implied source CAGR7.4%
increasing number of surgical proceduresrising prevalence of chronic diseasesincreasing prevalence of chronic diseases

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, Europe, North America. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Surgical And Medical Instruments And Apparatus news pulse

79,786available Prism news records
Latest 12m volume+4.4%33965 vs 32521 records
Positive classified tone64.3%+3.5 pp vs prior four quarters
2024-01: 2,737 mentions2024-02: 2,404 mentions2024-03: 2,556 mentions2024-04: 2,738 mentions2024-05: 2,865 mentions2024-06: 2,049 mentions2024-07: 2,013 mentions2024-08: 2,002 mentions2024-09: 1,991 mentions2024-10: 2,382 mentions2024-11: 2,524 mentions2024-12: 1,945 mentions2025-01: 2,748 mentions2025-02: 5,061 mentions2025-03: 3,814 mentions2025-04: 3,466 mentions2025-05: 2,526 mentions2025-06: 1,675 mentions2025-07: 3,108 mentions2025-08: 7,785 mentions2025-09: 2,523 mentions2025-10: 2,295 mentions2025-11: 1,880 mentions2025-12: 2,160 mentions2026-01: 1,555 mentions2026-02: 3,823 mentions2026-03: 3,271 mentions2026-04: 3,632 mentions2026-05: 258 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching instrument, medical, surgical. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

cannabis legalization debates
7,426
medical drama series
7,076
cannabis legalization trends & economic impact
6,204
recreational marijuana usage
5,294
in-flight medical emergency protocols
4,688
medical marijuana laws & regulatory frameworks
3,612

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

cannabis policy reform discussions 6,937marijuana legalization arguments 6,064cannabis industry regulations 5,877legal cannabis sales 5,788weed decriminalization debates 5,785medical cannabis regulations 5,271state cannabis economies 5,170state medical marijuana programs 5,154

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

increasing number of surgical procedures

9 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

cannabis legalization debates

7,426 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

6,337 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

uncertainty in reimbursements

6,911 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+4.4% news volume

The latest 12 months contain 33,965 matched records versus 32,521 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

64.3% positive · +3.5pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five currently eligible U.S.-listed issuers classified under SEC SIC 3841 (Surgical And Medical Instruments And Apparatus). The builder rechecks price, filing and Prism evidence before assembling the basket. This is a focused research comparison, not a complete sector index.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Surgical And Medical Instruments And Apparatus Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 13 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

Baxter has the widest attention-readiness rank gap

It ranks #1 by measured news attention (72.4%) and #5 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Baxter in Companies Radar

Dexcom shows a price-operating divergence to inspect

Its displayed filing-revenue change is +90.4% while its available monthly-close return is -30.9%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Dexcom in Companies Radar
Explanations

Attention measures coverage volume, not quality

Baxter's 72.4% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Baxter in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Dexcom's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 55/100 score.

Open Dexcom in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon